Skip to content
StockMarketAgent

ISRG vs MDT: side-by-side analysis

Cross-read of ISRG (Intuitive Surgical Inc.) versus MDT (MDT): ISRG looks meaningfully overvalued at $450 versus a fair-value midpoint of $255, while MDT appears in our peer table. Our current rating for ISRG is Sell.

Where ISRG and MDT sit on fair value

ISRG's composite fair-value range is $176–$337 (midpoint $255), versus a current price of $450. MDT is one of ISRG's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.

Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between ISRG and MDT is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.

Where they actually differ

ISRG is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. MDT, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 38.2× forward P/E with a PEG of 3.18 is not the same on ISRG as it is on MDT unless they share the same growth profile, capital intensity, and moat half-life.

ISRG's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against MDT should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.

Which one wins on each dimension

Valuation: ISRG looks meaningfully overvalued versus our fair-value midpoint. The full report's peer table compares ISRG and MDT directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for ISRG is bound by the kill-scenarios list in Section 2; the equivalent for MDT would need its own report. We do not co-rate two companies on a single page.

Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether ISRG or MDT is the better expression of the same theme.

Bottom line — ISRG or MDT?

Our rating for ISRG is Sell with a 87/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes MDT. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.

For the full evidence on ISRG, including the explicit peer multiples versus MDT and the rest of the comp set, see the canonical report at /stocks/isrg/analysis. For MDT's standalone report, see /stocks/mdt/analysis.

Frequently asked questions

ISRG vs MDT: which is cheaper today?

ISRG looks meaningfully overvalued at $450 versus a fair-value midpoint of $255 (range $176–$337). The peer table inside the full report compares ISRG and MDT directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.

Is ISRG a better buy than MDT?

Our current rating for ISRG is Sell; we do not co-rate MDT on this page — see MDT's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.

What archetype is ISRG?

Intuitive Surgical Inc. is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. MDT's own archetype is in its own report.

What is ISRG's moat score versus MDT?

ISRG's moat score is 9/10. The full moat section covers source, durability, and threat timeline; MDT's moat assessment is in its own standalone report.

Research for educational purposes. Not personalised investment advice. See the full ISRG report for the canonical evidence.